References
- Bonnet J., Loiseau A. M., Orvoen M., Bessin P. Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes. Agents and Actions 1981; 11: 559–562
- Fujita T., Tanayama S., Shirakawa Y., Suzuoki Z. Metabolic fate of ubiquinone-7. I. Absorption, excretion, and tissue distribution in rats. Journal of Biochemistry (Tokyo) 1971; 69: 53–61
- Imura Y., Terashita Z., Nishikawa K. Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988. Life Sciences 1986; 39: 111–117
- McManus L. M., Hanahan D. J., Demopoulos C. A., Pinkard R. N. Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet activating factor (PAF), in the rabbit. Journal of Immunology 1980; 124: 2919–2924
- Nakai Y., Kanai Y., Fugono T., Tanayama S. Metabolic fate of cephacetrile after parenteral administration in rats and rabbits. Journal of Antibiotics 1976; 29: 81–90
- Tanayama S., Shirakawa Y., Kanai Y., Suzuoki Z. Metabolism of 8-chloro-6-phenyl-4H-s-triazolo‘4, 3-a’ ‘1, 4’-benzodiazepine (D-40TA), a new central depressant. I. Absorption, distribution and excretion in rats. Xenobiotica 1974; 4: 33–47
- Tanayama S., Kobayashi T., Kanai Y. Metabolism of 3-(2′,4′,5′-triethoxybenzoyl)propionic acid, a new biliary smooth muscle relaxant with choleretic activity. I. Disposition after a single administration in rats and dogs. Xenobiotica 1978a; 8: 365–375
- Tanayama S., Yoshida K., Kanai Y. Metabolic fate of SCE-129, a new antipseudomonal cephalosporin, after parenteral administration in rats and dogs. Antimicrobial Agents and Chemotherapy 1978b; 14: 137–143
- Tanayama S., Yoshida K., Adachi K., Kondo T. Metabolic fate of SCE-1365, a new broad-spectrum cephalosporin, after parenteral administration to rats and dogs. Antimicrobial Agents and Chemotherapy 1980; 18: 511–518
- Terashita Z., Tsushima S., Yoshioka Y., Nomura H., Inada Y., Nishikawa K. CV- 3988-A specific antagonist of platelet activating factor (PAF). Life Sciences 1983; 32: 1975–1982
- Terashita Z., Imura Y., Nishikawa K. Inhibition by CV-3988 of the binding of ‘3H’-platelet activating factor (PAF) to the platelet. Biochemical Pharmacology 1985a; 34: 1491–1495
- Terashita Z., Imura Y., Nishikawa K., Sumida S. Is platelet activating factor (PAF) a mediator of endotoxin shock?. European Journal of Pharmacology 1985b; 109: 257–261
- Tsushima S., Yoshioka Y., Tanida S., Nomura N., Nojima S., Hozumi M. Syntheses and biological activities of N-alkyl- and N-alkenylcarbamoyl phospholipids. Chemical and Pharmaceutical Bulletin 1984; 32: 2700–2713
- Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (MULTI) for micro computer. Journal of Pharmacobio-Dynamics 1981; 4: 879–885